Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a publicly-traded, clinical-stage biopharmaceutical company structured around acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The company's primary focus is oncology, including treatment of chronic cancer pain, as well as developing therapeutic products for other indications, such as immunology and infectious diseases. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Sorrento is also developing CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. The firmalso has a cooperation framework agreement with LifeTech Scientific Corporation for the research and development, production, and commercialization of water-soluble cannabidiol and other water-soluble cannabinoids products
